Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.
Why pharma megamergers may become a relic of the past
Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.
